1399 related articles for article (PubMed ID: 30846338)
1. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338
[TBL] [Abstract][Full Text] [Related]
2. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
[TBL] [Abstract][Full Text] [Related]
3. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D
Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
[TBL] [Abstract][Full Text] [Related]
5. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
[TBL] [Abstract][Full Text] [Related]
6. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
Myhre PL; Prescott MF; Murphy SP; Fang JC; Mitchell GF; Ward JH; Claggett B; Desai AS; Solomon SD; Januzzi JL
JACC Heart Fail; 2022 Feb; 10(2):119-128. PubMed ID: 35115085
[TBL] [Abstract][Full Text] [Related]
7. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau J; Shi VC; Solomon SD; Swedberg K; Zile MR;
Eur J Heart Fail; 2013 Sep; 15(9):1062-73. PubMed ID: 23563576
[TBL] [Abstract][Full Text] [Related]
8. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
[TBL] [Abstract][Full Text] [Related]
10. Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays.
Ibrahim NE; McCarthy CP; Shrestha S; Gaggin HK; Mukai R; Szymonifka J; Apple FS; Burnett JC; Iyer S; Januzzi JL
J Am Coll Cardiol; 2019 Mar; 73(11):1273-1284. PubMed ID: 30898202
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.
Kristensen SL; Jhund PS; Mogensen UM; Rørth R; Abraham WT; Desai A; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV;
Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29018174
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
[TBL] [Abstract][Full Text] [Related]
13. Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial.
Butt JH; Ibrahim W; Dewan P; Desai AS; Køber L; Prescott MF; Lefkowitz MP; Rouleau JL; Solomon SD; Zile MR; Packer M; Jhund PS; McMurray JJV
Circ Heart Fail; 2023 Mar; 16(3):e010111. PubMed ID: 36943907
[TBL] [Abstract][Full Text] [Related]
14. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
[TBL] [Abstract][Full Text] [Related]
15. Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy.
Maisel AS; Daniels LB; Anand IS; McCullough PA; Chow SL
Postgrad Med; 2018 Apr; 130(3):299-307. PubMed ID: 29596012
[TBL] [Abstract][Full Text] [Related]
16. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
17. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
[TBL] [Abstract][Full Text] [Related]
18. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
19. BNP and NT-proBNP Interpretation in the Neprilysin Inhibitor Era.
Sbolli M; deFilippi C
Curr Cardiol Rep; 2020 Sep; 22(11):150. PubMed ID: 32951154
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
Velazquez EJ; Morrow DA; DeVore AD; Ambrosy AP; Duffy CI; McCague K; Hernandez AF; Rocha RA; Braunwald E
Am Heart J; 2018 Apr; 198():145-151. PubMed ID: 29653636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
